Rheumatoid arthritis Rheumatoid arthritis
Conditions
Interventions
None listed
Sponsors
Yamaoka Kunihiro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients aged 20 years old and older as of the index date and the reason for receiving peficitinib during peficitinib PMS (SMR001) is RA 2.Patients who were administered MTX (oral formulation: 8 mg/week higher or subcutaneous injection preparation: 7.5 mg/week higher ) concomitantly at the start of initial administration with peficitinib 100 mg or 150 mg 3.Patients who are registered to Peficitinib PMS (SMR001) 4.Patients who provided written informed consent to study participation 5.Patients who have been followed up for at least 104 weeks from the index date (including those who are discontinued before 104 weeks)
Exclusion criteria
Exclusion criteria: 1.Patients who were administered Peficitinib for diseases other than RA 2.Patients who were administered Peficitinib 50 mg from the index date to 104 weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in CDAI | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Adverse Events and adverse reactions after the start of peficitinib administration 2)DAS28-ESR 3)DAS28-CRP 4)SDAI 5)CDAI 6)The change in the subjective global assessment 7)The change in the physician global assessment 8)The change in tender joint count 9)The change in swollen joint count 10)The change in ESR 11)The change in CRP 12)Dose reduction 13)Association between the patient characteristics and MTX dose level reduction 14)Determination of Good response/Moderate response based on DAS28-ESR EULAR improvement criteria | — |
Contacts
Public ContactKunihiro Yamaoka
Kitasato University Hospial
Outcome results
None listed